High plasma levels of endothelin-1 in untreated Addison's disease

Letizia C, Centanni M, Scuro L, Canettieri G, Cerci S, De Ciocchis A, D'Ambrosio C, Scavo D. High plasma levels of endothelin 1 in untreated Addison's disease. Eur J Endocrinol 1996;135:696–9. ISSN 0804–4643 The aim of this study has been to investigate the plasma endothelin-1 (ET-1) level...

Full description

Saved in:
Bibliographic Details
Published in:European journal of endocrinology 1996-12, Vol.135 (6), p.696-699
Main Authors: LETIZIA, C, CENTANNI, M, SCURO, L, CANETTIERI, G, CERCI, S, DE CIOCCHIS, A, D'AMBROSIO, C, SCAVO, D
Format: Article
Language:English
Subjects:
Addison Disease - blood
Addison Disease - drug therapy
Addison Disease - physiopathology
Adrenals. Adrenal axis. Renin-angiotensin system (diseases)
Adult
Animals
Anti-Inflammatory Agents - pharmacology
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
CLINICAL STUDIES
Endocrinopathies
Endothelin-1 - blood
Endothelin-1 - drug effects
Endothelin-1 - immunology
Female
Fludrocortisone - pharmacology
Fludrocortisone - therapeutic use
Hemodynamics - drug effects
Humans
Hydrocortisone - pharmacology
Hydrocortisone - therapeutic use
Immune Sera - immunology
Male
Medical sciences
Middle Aged
Mineralocorticoids - pharmacology
Mineralocorticoids - therapeutic use
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Rabbits
Radioimmunoassay
Reference Values
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Letizia C, Centanni M, Scuro L, Canettieri G, Cerci S, De Ciocchis A, D'Ambrosio C, Scavo D. High plasma levels of endothelin 1 in untreated Addison's disease. Eur J Endocrinol 1996;135:696–9. ISSN 0804–4643 The aim of this study has been to investigate the plasma endothelin-1 (ET-1) levels in adult patients with proven Addison's disease (AD). Plasma ET-1 levels were measured in 29 subjects (17 males and 12 females, aged between 20 and 54 years): 15 of them were patients with AD and 14 were sex- and age-matched normal subjects, used as a control group. All patients with AD have been studied under basal conditions and nine of them also after 2 weeks on oral corticosteroid therapy (individual cortisol dosage ranging from 25 to 37.5 mg/day and 0.1 mg/day 9α-fluorohydrocortisone). Extracted plasma ET-1 was determined by a specific radioimmunoassay using rabbit endothelin antisera. Mean ET-1 values in the patients with AD were three times higher than in normal subjects (21.09 ± 4.38 pg/ml vs 6.72 ± 1.74 pg/ml; p < 0.0001). Plasma ET-1 levels assayed in the patients with AD after 2 weeks of corticosteroid therapy were significantly decreased (14.47 ± 3.7 pg/ml vs 22.8 ± 5.2 pg/ml; −37%; p < 0.001) compared to values in untreated patients. However, the plasma ET-1 values obtained following corticosteroid therapy were still significantly higher (p < 0.001) than those detected in the control subjects. These results clearly indicate that patients with untreated AD have increased circulating ET-1 levels that may be reduced by short-term corticosteroid therapy. Claudio Letizia, Policlinico Umberto I, II Clinica Medica, 00185 Roma, Italy
ISSN:0804-4643
1479-683X
DOI:10.1530/eje.0.1350696